gamesinvestor
04 Aug 2017
Falling like a stone This seems so strange -- the results were good, the stock jumped up 4.7% on the day then fell and fell and fell?Games
gamesinvestor
04 Aug 2017
Telegraph update This article mentions the dual listing possibility with some uncertainty about neuroscience being listed in London or New York -- the latter being the most likely because the US market is the biggest for ADHD :-[link]
Thedarkkn1ght
03 Aug 2017
Re: 'Dirt cheap' P/E of 10.7 is a hard fact and can not be denied. This is low for any business/sector especially Pharma and even more so for a growing company.A string of large buys went through after close.
dazurtrader
03 Aug 2017
Not cheap enough SHP hit my long term stop today, so I am out after holding for four years.I'm reinvesting the cash in health care rather than pharma. The trend for SHP has been down for many months and I think that slow decline will continue. The cycle may turn, or a buyer appear, but tight now I'm moving to the end user part of health care rather than a component supplier.So, still over priced or cheap enough? Time will tell
Thedarkkn1ght
03 Aug 2017
'Dirt cheap' SHIRE is a stock I’ve had earmarked as seriously undervalued for some time. The price has retreated to 4,200p since the initial spike and I continue to view it as a dirt-cheap buy.Strong long-term prospectsShire catapulted itself into the position of world leader in rare diseases with its $32bn acquisition of US firm Baxalta in June last year. Today’s results show the merger is already bearing richer fruit than anticipated. Shire has over-delivered on first-year integration cost synergies, recognising $400m versus its $300m target and putting it ahead of schedule to deliver at least $700m by year three.The company advised that the first-half performance was driven by significant contributions across its broad and diverse portfolio. And with the strength and scale of the enlarged group, I’m not surprised that Flemming Ornskov commented that the board is “very confident about Shire’s long-term prospects.”The group’s rare disease and neuroscience businesses are both performing strongly and each has significant growth potential over the coming years. In fact, management is evaluating strategic options for the neuroscience franchise, including the potential for its independent public listing. It expects to complete this evaluation by year-end.Generous valuationToday’s updated guidance on full-year earnings increased the mid-range point for diluted earnings per American Depositary Share (ADS) to $15 from $14.90. Each ADS is equivalent to three ordinary shares, so we’re looking at ordinary earnings per share (EPS) of $5, or 379p at current exchange rates.The price-to-earnings (P/E) ratio is 11.1. This looks far too generous to me for a company with Shire’s long-term growth credentials.[link]
the roaster
03 Aug 2017
Re: Bid Talk Agree.Too much of a roller coaster for me.Good news aplenty but down and down it goes.I'm out soon as I break even £45
The White Rider
03 Aug 2017
Re: Bid Talk I have never known a share see-saw as much as this.
gamesinvestor
03 Aug 2017
Re: Bid Talk and it's gone back in the red after climbing 4.7% earlier.Someone doesn't like the results, which on the surface looked excellent.Games
The White Rider
03 Aug 2017
Re: Bid Talk Results were out at 12.00 - see under news.A bit too technical for me but seemed positive and talk about a partial spin-off. Good to see a positive reaction as I've been in the red ever since buying into Shire.DYO
gamesinvestor
03 Aug 2017
Results out Where is everyone?[link]
gamesinvestor
03 Aug 2017
Rising fast Share Price up 4.38% as I type, something is happening here?Games
gamesinvestor
03 Aug 2017
Bid Talk [link] entered a price monitoring extension at 12
2 today as a buy order looks like it was greater than the 5% within which SETS normally operates.Something going on here and the resuts are supposed to be out today, where are they?Games
philanderer
21 Jul 2017
Re: Share price collapse Competitive threat of Roche / Chugai's new monoclonal antibody, emicizumab (a new once-weekly subq injection for the treatment of hemophilia A), becoming a new treatment alternative for hemophilia patients[link]
